Patent intelligence · US
US 10806716
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
Patent details — US 10806716
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 20, 2020
- Expiration
- Oct 15, 2040
- Applicant
- Auransa Inc.
- Claims
- 12
- CPC classes
- A61K, A61K31/136, A61K31/352, A61K31/353
Quick answer
US 10806716 (Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity) is held by Auransa Inc.. Status: granted. Granted Oct 20, 2020. Expires Oct 15, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Auransa Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/136, A61K31/352, A61K31/353, A61K31/404, A61K31/44
More from Auransa Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11786503
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 11166936
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10874633
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10688172
HPV particles and uses thereof
granted -
US 10596275
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
granted -
US 10300150
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
granted -
US 10179168
HPV particles and uses thereof
granted
Frequently asked questions
What is US patent 10806716?
US 10806716 (Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity) is held by Auransa Inc.. Status: granted. Granted Oct 20, 2020. Expires Oct 15, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10806716?
Auransa Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 10806716 expire?
Our index shows an expiration date of Oct 15, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.